Trends in and patterns of obesity reduction medication use in an insured cohort

Obesity

Volumn 18, Issue 1, 2010, Pages 206-209

  Bolen, Shari D ^a   Clark, Jeanne M ^b,c,d   Richards, Thomas M ^d   Shore, Andrew D ^d   Goodwin, Suzanne M ^d   Weiner, Jonathan P ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; PRESCRIPTION DRUG;

ARTICLE; DRUG UTILIZATION; FEMALE; HUMAN; MALE; OBESITY; UNITED STATES;

ANTI-OBESITY AGENTS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; OBESITY; PRESCRIPTION DRUGS; UNITED STATES;

EID: 73949126465     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.175     Document Type: Article

References (17)

1. U.S. Obesity Trends 1985-2005. http://www.cdc.gov/nccdphp/dnpa/obesity/ trend/maps/index.htm. Accessed 24 July 2007.
2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
3. Flegal KM, Graubard BI, Williamson D F, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-1867.
4. Must A, Spadano J, Coakley EH et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-1529.
5. Ruser CB, Sanders L, Brescia GR et al. Identification and management of overweight and obesity by internal medicine residents. J Gen Intern Med 2005;20:1139-1141.
6. Lemay CA, Cashman S, Savageau J et al. Underdiagnosis of obesity at a community health center. J Am Board Fam Pract 2003;16:14-21.
7. Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-546.
8. Encinosa WE, Bernard DM, Steiner CA, Chen CC. Use and costs of bariatric surgery and prescription weight-loss medications. Health Aff (Millwood) 2005;24:1039-1046.
9. Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med 2003;163:1046-1050.
10. Cerner Multum. http://www.multum.com/2005. (2005). Accessed June 2005
11. Physicians' Desk Reference. 59th edn. Thomson PDR: Montvale, NJ, 2005.
12. Weiner J, Abrams C, Kaplowitz C. The Johns Hopkins University ACG case-mix system. (2002). http://www.acg.jhsph.edu/ACGDocuments/newsletter-f2002. pdf. Accessed 9 January 2007.
13. Widgren S. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramin. Arch Pathol Lab Med 2000;124:801-802.
14. Fiscella K, Holt K, Meldrum S, Franks P. Disparities in preventive procedures: comparisons of self-report and Medicare claims data. BMC Health Serv Res 2006;6:122.
15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602. (Pubitemid 40973434)
16. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007;64:566-576.
17. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD; DARTS/ MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-488.